Literature DB >> 17878354

Killing kinetics of simian immunodeficiency virus-specific CD8+ T cells: implications for HIV vaccine strategies.

Erik Rollman1, Miranda Z Smith, Andrew G Brooks, Damian F J Purcell, Bartek Zuber, Ian A Ramshaw, Stephen J Kent.   

Abstract

Both the magnitude and function of vaccine-induced HIV-specific CD8+ CTLs are likely to be important in the outcome of infection. We hypothesized that rapid cytolysis by CTLs may facilitate control of viral challenge. Release kinetics of the cytolytic effector molecules granzyme B and perforin, as well as the expression of the degranulation marker CD107a and IFN-gamma were simultaneously studied in SIV Gag(164-172) KP9-specific CD8+ T cells from Mane-A*10+ pigtail macaques. Macaques were vaccinated with either prime-boost poxvirus vector vaccines or live-attenuated SIV vaccines. Prime-boost vaccination induced Gag-specific CTLs capable of only slow (after 3 h) production of IFN-gamma and with limited (<5%) degranulation and granzyme B release. Vaccination with live-attenuated SIV resulted in a rapid cytolytic profile of SIV-specific CTLs with rapid (<0.5 h) and robust (>50% of tetramer-positive CD8+ T cells) degranulation and granzyme B release. The cytolytic phenotype following live-attenuated SIV vaccinations were similar to that associated with the partial resolution of viremia following SIV(mac251) challenge of prime-boost-vaccinated macaques, albeit with less IFN-gamma expression. High proportions of KP9-specific T cells expressed the costimulatory molecule CD28 when they exhibited a rapid cytolytic phenotype. The delayed cytolytic phenotype exhibited by standard vector-based vaccine-induced CTLs may limit the ability of T cell-based HIV vaccines to rapidly control acute infection following a pathogenic lentiviral exposure.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17878354     DOI: 10.4049/jimmunol.179.7.4571

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Differential antigen presentation kinetics of CD8+ T-cell epitopes derived from the same viral protein.

Authors:  Jonah B Sacha; Matthew R Reynolds; Matthew B Buechler; Chungwon Chung; Anna K Jonas; Lyle T Wallace; Andrea M Weiler; Wonhee Lee; Shari M Piaskowski; Taeko Soma; Thomas C Friedrich; Nancy A Wilson; David I Watkins
Journal:  J Virol       Date:  2008-07-02       Impact factor: 5.103

2.  Protective attenuated lentivirus immunization induces SIV-specific T cells in the genital tract of rhesus monkeys.

Authors:  M Genescà; P J Skinner; K M Bost; D Lu; Y Wang; T L Rourke; A T Haase; M B McChesney; C J Miller
Journal:  Mucosal Immunol       Date:  2008-03-05       Impact factor: 7.313

3.  Timing of immune escape linked to success or failure of vaccination.

Authors:  Jeanette C Reece; Liyen Loh; Sheilajen Alcantara; Caroline S Fernandez; John Stambas; Amy Sexton; Robert De Rose; Janka Petravic; Miles P Davenport; Stephen J Kent
Journal:  PLoS One       Date:  2010-09-16       Impact factor: 3.240

4.  Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects.

Authors:  Ivan Stratov; Amy Chung; Stephen J Kent
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

5.  With minimal systemic T-cell expansion, CD8+ T Cells mediate protection of rhesus macaques immunized with attenuated simian-human immunodeficiency virus SHIV89.6 from vaginal challenge with simian immunodeficiency virus.

Authors:  Meritxell Genescà; Pamela J Skinner; Jung Joo Hong; Jun Li; Ding Lu; Michael B McChesney; Christopher J Miller
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

Review 6.  Antiviral CD8+ T cells in the genital tract control viral replication and delay progression to AIDS after vaginal SIV challenge in rhesus macaques immunized with virulence attenuated SHIV 89.6.

Authors:  M Genescà; M B McChesney; C J Miller
Journal:  J Intern Med       Date:  2009-01       Impact factor: 8.989

7.  Early antiretroviral treatment prevents the development of central nervous system abnormalities in simian immunodeficiency virus-infected rhesus monkeys.

Authors:  Maria Cecilia G Marcondes; Claudia Flynn; Salvador Huitron-Rezendiz; Debbie D Watry; Michelle Zandonatti; Howard S Fox
Journal:  AIDS       Date:  2009-06-19       Impact factor: 4.177

8.  Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans.

Authors:  David I Watkins; Dennis R Burton; Esper G Kallas; John P Moore; Wayne C Koff
Journal:  Nat Med       Date:  2008-06       Impact factor: 53.440

9.  Limited maintenance of vaccine-induced simian immunodeficiency virus-specific CD8 T-cell receptor clonotypes after virus challenge.

Authors:  Miranda Z Smith; Tedi E Asher; Vanessa Venturi; Miles P Davenport; Daniel C Douek; David A Price; Stephen J Kent
Journal:  J Virol       Date:  2008-05-28       Impact factor: 5.103

10.  Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239.

Authors:  Bin Jia; Sharon K Ng; M Quinn DeGottardi; Michael Piatak; Eloísa Yuste; Angela Carville; Keith G Mansfield; Wenjun Li; Barbra A Richardson; Jeffrey D Lifson; David T Evans
Journal:  PLoS Pathog       Date:  2009-01-23       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.